Colorectal disorders:
Indications for: AMITIZA
Irritable bowel syndrome with constipation (IBS–C) in women.
Adult Dosage:
Swallow whole. Take with food and water. ≥18yrs: 8mcg twice daily. Severe hepatic impairment (Child-Pugh Class C): initially 8mcg once daily; if tolerated and inadequate response, may escalate to full dose; monitor.
Children Dosage:
<18yrs: not established.
AMITIZA Contraindications:
Known or suspected mechanical GI obstruction.
AMITIZA Warnings/Precautions:
Confirm absence of GI obstruction before starting therapy. Severe diarrhea: not recommended. Hepatic impairment. Reevaluate periodically. Pregnancy. Nursing mothers; monitor infants for diarrhea.
AMITIZA Classification:
GI motility enhancer (chloride channel activator).
AMITIZA Interactions:
Possibly antagonized by diphenylheptane opioids (eg, methadone). Increased risk of syncope/hypotension with antihypertensives.
Adverse Reactions:
Nausea, diarrhea (discontinue if severe), abdominal pain; syncope, hypotension, dyspnea.
Generic Drug Availability:
YES
How Supplied:
8mcg—60; 24mcg—60, 100
Constipation and bowel cleansers:
Indications for: AMITIZA
Chronic idiopathic constipation. Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation.
Limitations of Use:
Effectiveness in the treatment of OIC in patients taking diphenylheptane opioids (eg, methadone) has not been established.
Adult Dosage:
Swallow whole. Take with food and water. 24mcg twice daily. Moderate hepatic impairment (Child-Pugh Class B): initially 16mcg twice daily. Severe hepatic impairment (Child-Pugh Class C): initially 8mcg twice daily. If tolerated and inadequate response, may escalate to full dose; monitor.
Children Dosage:
Not established.
AMITIZA Contraindications:
Known or suspected mechanical GI obstruction.
AMITIZA Warnings/Precautions:
Confirm absence of GI obstruction before starting therapy. Severe diarrhea: not recommended. Hepatic impairment. Reevaluate periodically. Pregnancy. Nursing mothers; monitor infants for diarrhea.
AMITIZA Classification:
GI motility enhancer (chloride channel activator).
AMITIZA Interactions:
Possibly antagonized by diphenylheptane opioids (eg, methadone). Increased risk of syncope/hypotension with antihypertensives.
Adverse Reactions:
Nausea, diarrhea (discontinue if severe), headache, abdominal pain, abdominal distension, flatulence; syncope, hypotension, dyspnea.
Generic Drug Availability:
YES
How Supplied:
8mcg—60; 24mcg—60, 100
